New Advances In Treating Stage IV Cancer kashmirreader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kashmirreader.com Daily Mail and Mail on Sunday newspapers.
Pantai Jerudong Specialist Centre (PJSC) on Wednesday launched ‘Movember’ to mark Men’s Health awareness for the whole month of November. This year, The Brunei Cancer Centre (TBCC) organised a public forum focusing on strengthening men’s health through a holistic approach. The forum serves as a platform to foster awareness, knowledge, and open dialogue on various […]
Study provides new insight on how HER2-low tumors may evolve in breast cancer patients
The finding that breast tumors can evolve to express low HER2 potentially widens the number of patients who can benefit from new investigational agents, typically novel antibody-drug conjugate therapies, that are currently in clinical trials for HER2-low tumors.
The first study of its kind exploring how breast cancers change from the primary to the recurrent tumor has revealed that nearly 30% of breast cancer patients convert from, or to, human epidermal growth factor receptor (HER)2-low status. Specifically, the study found that 14% of triple-negative breast cancers with HER2-negative expression (also referred to as HER2-0) in the primary tumor converted to HER2-low expression in the recurrent tumor possibly offering an option to such hard-to-treat tumors.
Switch of breast tumors to HER2-low might provide greater therapeutic options ANI | Updated: May 09, 2021 18:56 IST
Lugano [Switzerland], May 9 (ANI): The finding that breast tumours can evolve to express low HER2 potentially widens the number of patients who can benefit from new investigational agents, typically novel antibody-drug conjugate therapies, that are currently in clinical trials for HER2-low tumours.
The first study of its kind exploring how breast cancers change from the primary to the recurrent tumour has revealed that nearly 30% of breast cancer patients convert from, or to, human epidermal growth factor receptor (HER)2-low status. The study was published in the journal Annals of Oncology.
European Society for Medical Oncology
The finding that breast tumours can evolve to express low HER2 potentially widens the number of patients who can benefit from new investigational agents, typically novel antibody-drug conjugate therapies, that are currently in clinical trials for HER2-low tumours.
The first study of its kind exploring how breast cancers change from the primary to the recurrent tumour has revealed that nearly 30% of breast cancer patients convert from, or to, human epidermal growth factor receptor (HER)2-low status. Specifically, the study found that 14% of triple-negative breast cancers with HER2-negative expression (also referred to as HER2-0) in the primary tumour converted to HER2-low expression in the recurrent tumour possibly offering an option to such hard-to-treat tumours.
‘Cancer mortality rate can be halved with early detection’
Updated:
Updated:
Share Article
AAA
Cancer mortality rate can be halved with early detection. Only when cancer is diagnosed after the disease advances to terminal stage, many patients die. The success rate of treatments for all forms of cancer is increasing – in some cases up to 99%, according to medical experts of Meenakshi Mission Hospital and Research Centre here.
Addressing the media on Wednesday ahead of World Cancer Day that falls on February 4, the medical experts said the country could reduce cancer deaths by popularising preventive health check-ups and investing in medical infrastructure for comprehensive early detection and treatment. They stressed the need for a balanced diet, an active lifestyle and avoiding smoking, tobacco chewing and alcohol consumption.